Julie Barron
Research Subjects
Research Interests
Julie Barron has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Moss Herberholz
The Radical Well-Being Center, Southfield, MI, USA
8 shared publications- Daniel J. Kruger
University of Michigan
6 shared publications Kevin F. Boehnke
Michigan Psychedelic Center (M-PsyC), University of Michigan, Ann Arbor, MI, USA; Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA
6 shared publicationsJacob S. Aday
Michigan Psychedelic Center, University of Michigan Medical School, Ann Arbor, USA
4 shared publicationsDaniel J. Kruger
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, USA
3 shared publications- Kevin F. Boehnke
Anesthesiology Department, University of Michigan Medical School, and Michigan Psychedelic Center, University of Michigan, Ann Arbor, Michigan
3 shared publications
Latest Publications
- Open Access
- 23 August 2026
- Published by MDPI AG in Social Sciences
- Vol. 15 (9) , 569
Perceptions of Psychedelic Decriminalization: Findings from a Community Survey of People Who Use Psychedelics
Psychedelic decriminalization has moved from the margins of drug-policy discourse to a mainstream public health and equity conversation. This community survey reveals that people with psychedelic experience who live in areas that have decriminalized psychedelics report greater benefits of psychedelic decriminalization than adverse outcomes. In decriminalized zones, most (84.0%) participants (N = 163) reported feeling improvements in one of the following areas because of decriminalization: legal risks, social acceptance, substance availability, substance safety, diversity of available products, and overall substance quality. Only 5.5% of participants reported worsened conditions in any category. Most (74.8%) participants also reported decriminalization-related improvements related to psychedelic therapy, such as social acceptance, availability, legal risks, safety, and diversity of services available. Notably, no participant reported that legal risk had worsened. Post decriminalization, most (72.4%) participants reported improvements in life conditions including stress and anxiety, worry, depressive symptoms, physical health, addiction, family relationships, other relationships, connection to community, working conditions, and financial status. Only 8.6% of participants reported declines in any category regarding psychedelic therapy or life conditions (2.5%). Although our methodology precludes attributions of causality, this initial study may inspire research with more sophisticated methodologies.
- 23 August 2026
- Published by MDPI AG in Social Sciences
- Vol. 15 (9) , 569
Open AccessPerceptions of Psychedelic Decriminalization: Findings from a Community Survey of People Who Use Psychedelics
Psychedelic decriminalization has moved from the margins of drug-policy discourse to a mainstream public health and equity conversation. This community survey reveals that people with psychedelic experience who live in areas that have decriminalized psychedelics report greater benefits of psychedelic decriminalization than adverse outcomes. In decriminalized zones, most (84.0%) participants (N = 163) reported feeling improvements in one of the following areas because of decriminalization: legal risks, social acceptance, substance availability, substance safety, diversity of available products, and overall substance quality. Only 5.5% of participants reported worsened conditions in any category. Most (74.8%) participants also reported decriminalization-related improvements related to psychedelic therapy, such as social acceptance, availability, legal risks, safety, and diversity of services available. Notably, no participant reported that legal risk had worsened. Post decriminalization, most (72.4%) participants reported improvements in life conditions including stress and anxiety, worry, depressive symptoms, physical health, addiction, family relationships, other relationships, connection to community, working conditions, and financial status. Only 8.6% of participants reported declines in any category regarding psychedelic therapy or life conditions (2.5%). Although our methodology precludes attributions of causality, this initial study may inspire research with more sophisticated methodologies.
- 2 June 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 201, 1-6
Priorities for psychedelic research among people who use psychedelics
- 2 June 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 201, 1-6
Priorities for psychedelic research among people who use psychedelics
- Open Access
- 15 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically
Psychedelic drugs show promise in facilitating a variety of long-term psychological changes, but they may also lead to unexpected major life changes that have not been captured by measures typically used in clinical trials. The Psychedelic-related Major Life Changes Questionnaire (P-MLCQ) was created to assess psychedelic-related major life changes across 10 different domains and evaluated in a sample reporting naturalistic psychedelic use (N = 581). 482/581 participants (82.96%) reported at least one major life change influenced by their psychedelic use (M = 3.29, SD = 2.60), including changes in Goals (53.70%), Values (53.53%), Religion/spirituality (49.05%), Social activities (37.01%), Eating habits/diet (34.08%), Occupation/Line of work (32.36%), Hobbies (29.43%), Political views (14.97%), Sexuality (13.08%), and Marital status/non-marital partner change (12.22%). Major life changes were rated highly positively (M = 4.64, SD = 0.61 on a 5-point scale). There was a positive relationship between frequency of psychedelic use over the last five years and total number of psychedelic-related major life changes (r = 0.34, p < 0.001). Women were 21% more likely than men to report major life changes, whereas age and education-level were negatively related to major life changes. Although our results support that psychedelic use can be followed by major life changes, future research is needed to examine the generalizability of these results in representative samples that are less susceptible to positive bias.
- 15 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessMajor life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically
Psychedelic drugs show promise in facilitating a variety of long-term psychological changes, but they may also lead to unexpected major life changes that have not been captured by measures typically used in clinical trials. The Psychedelic-related Major Life Changes Questionnaire (P-MLCQ) was created to assess psychedelic-related major life changes across 10 different domains and evaluated in a sample reporting naturalistic psychedelic use (N = 581). 482/581 participants (82.96%) reported at least one major life change influenced by their psychedelic use (M = 3.29, SD = 2.60), including changes in Goals (53.70%), Values (53.53%), Religion/spirituality (49.05%), Social activities (37.01%), Eating habits/diet (34.08%), Occupation/Line of work (32.36%), Hobbies (29.43%), Political views (14.97%), Sexuality (13.08%), and Marital status/non-marital partner change (12.22%). Major life changes were rated highly positively (M = 4.64, SD = 0.61 on a 5-point scale). There was a positive relationship between frequency of psychedelic use over the last five years and total number of psychedelic-related major life changes (r = 0.34, p < 0.001). Women were 21% more likely than men to report major life changes, whereas age and education-level were negatively related to major life changes. Although our results support that psychedelic use can be followed by major life changes, future research is needed to examine the generalizability of these results in representative samples that are less susceptible to positive bias.
- Open Access
- 25 November 2025
- Published by Springer Nature in Harm Reduction Journal
- Vol. 22 (1) , 191
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community
Background: The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated clinical and research settings. We employed a community-based approach to crowdsource practical recommendations for first-time psychedelic experiences from the psychedelic community. Methods: We conducted an online survey with 581 individuals who reported psychedelic use ( N = 581) on recommendations for people using psychedelics for the first-time, following the principles of community-based collaborative research. The survey assessed recommendations for and against specific psychedelics for first-time experiences, recommendations for and against combinations of psychedelics, and other advice for first-time experiences. Open-ended follow-up questions were included to understand participants' reasons for their recommendations. An experienced qualitative researcher and two qualitative coders analyzed responses to open-ended items. Results: Most participants recommended psilocybin for first-time psychedelic experiences, approximately half recommended cannabis, and a third recommended MDMA/MDA (3,4-methylenedioxymethamphetamine/3,4-methylenedioxyamphetamine, ecstasy, molly). These substances were favored for their moderate intensity, dose-dependent effects, precise dosing, and relatively short duration of effects. Conversely, substances such as ayahuasca, DMT ( N , N -dimethyltryptamine), 5-MeO-DMT (5-methoxy- N , N -dimethyltryptamine), and Salvia divinorum or salvinorin A were not recommended due to their intensity, mental and physical health risks, and safety concerns. Participants advised against mixing psychedelics with alcohol, stimulants, antidepressants, and narcotics/opiates. Additional recommendations included embracing the experience, learning about the substance and its effects, and setting intentions for the experience. Conclusions: Given the growing interest in psychedelics despite limited legal access and systematic education available, it is crucial to inform the public about practices that minimize risks. This project compiled recommendations from individuals who self-identified being experienced with psychedelics. The active involvement of the psychedelic community may enhance research quality and public trust in the findings.
- 25 November 2025
- Published by Springer Nature in Harm Reduction Journal
- Vol. 22 (1) , 191
Open AccessBest practices for first psychedelic experiences: harm reduction advice from the psychedelic community
Background: The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated clinical and research settings. We employed a community-based approach to crowdsource practical recommendations for first-time psychedelic experiences from the psychedelic community. Methods: We conducted an online survey with 581 individuals who reported psychedelic use ( N = 581) on recommendations for people using psychedelics for the first-time, following the principles of community-based collaborative research. The survey assessed recommendations for and against specific psychedelics for first-time experiences, recommendations for and against combinations of psychedelics, and other advice for first-time experiences. Open-ended follow-up questions were included to understand participants' reasons for their recommendations. An experienced qualitative researcher and two qualitative coders analyzed responses to open-ended items. Results: Most participants recommended psilocybin for first-time psychedelic experiences, approximately half recommended cannabis, and a third recommended MDMA/MDA (3,4-methylenedioxymethamphetamine/3,4-methylenedioxyamphetamine, ecstasy, molly). These substances were favored for their moderate intensity, dose-dependent effects, precise dosing, and relatively short duration of effects. Conversely, substances such as ayahuasca, DMT ( N , N -dimethyltryptamine), 5-MeO-DMT (5-methoxy- N , N -dimethyltryptamine), and Salvia divinorum or salvinorin A were not recommended due to their intensity, mental and physical health risks, and safety concerns. Participants advised against mixing psychedelics with alcohol, stimulants, antidepressants, and narcotics/opiates. Additional recommendations included embracing the experience, learning about the substance and its effects, and setting intentions for the experience. Conclusions: Given the growing interest in psychedelics despite limited legal access and systematic education available, it is crucial to inform the public about practices that minimize risks. This project compiled recommendations from individuals who self-identified being experienced with psychedelics. The active involvement of the psychedelic community may enhance research quality and public trust in the findings.
- 28 March 2025
- Published by Taylor & Francis in The Journal of Sex Research
- Vol. 63 (7) , 1-12
Perceived Impact of Psychedelics on Sexual, Gender, and Intimate Relationship Dynamics: A Mixed-Methods Investigation
Systematic research on the impact of psychedelic use on sexuality and intimacy remains limited. This study investigated reported effects of psychedelic use on various aspects of sexuality, gender, and relationships through an online survey of individuals who had used psychedelics (N = 581). Most participants (70.2%) reported perceived impacts of psychedelic experiences on their sexuality and/or sexual experiences, with 65.4% noting short-term effects during psychedelic experiences and 52.8% reporting long-term effects, although no individual effect was endorsed by most participants. A higher proportion of participants indicated that psychedelic experiences enhanced, rather than diminished, relationship quality, attraction to current partners, and sexual activities. Approximately 10% of participants reported that psychedelic experiences influenced their gender identity and/or expression, reporting increased authenticity, self-acceptance, openness, and freedom in self-expression, as well as altered experiences of sexuality and gender. One-quarter of women and one-eighth of men reported heightened same-sex attraction following psychedelic use, and one-third of those with other gender identities reported changes in sexual attraction. Higher proportions of participants reported dating multiple people, being polyamorous or in an open relationship, or being committed to only one person after their psychedelic experiences compared to before. Regression models identified various perceived effects associated with using large psychedelic doses, more frequent psychedelic use, lower household income, identifying as gender diverse, and especially younger age and identifying as women. Psychedelics may facilitate these changes via self-insight, greater connectedness with others, and increases in self-compassion, though further research is needed.
- 28 March 2025
- Published by Taylor & Francis in The Journal of Sex Research
- Vol. 63 (7) , 1-12
Perceived Impact of Psychedelics on Sexual, Gender, and Intimate Relationship Dynamics: A Mixed-Methods Investigation
Systematic research on the impact of psychedelic use on sexuality and intimacy remains limited. This study investigated reported effects of psychedelic use on various aspects of sexuality, gender, and relationships through an online survey of individuals who had used psychedelics (N = 581). Most participants (70.2%) reported perceived impacts of psychedelic experiences on their sexuality and/or sexual experiences, with 65.4% noting short-term effects during psychedelic experiences and 52.8% reporting long-term effects, although no individual effect was endorsed by most participants. A higher proportion of participants indicated that psychedelic experiences enhanced, rather than diminished, relationship quality, attraction to current partners, and sexual activities. Approximately 10% of participants reported that psychedelic experiences influenced their gender identity and/or expression, reporting increased authenticity, self-acceptance, openness, and freedom in self-expression, as well as altered experiences of sexuality and gender. One-quarter of women and one-eighth of men reported heightened same-sex attraction following psychedelic use, and one-third of those with other gender identities reported changes in sexual attraction. Higher proportions of participants reported dating multiple people, being polyamorous or in an open relationship, or being committed to only one person after their psychedelic experiences compared to before. Regression models identified various perceived effects associated with using large psychedelic doses, more frequent psychedelic use, lower household income, identifying as gender diverse, and especially younger age and identifying as women. Psychedelics may facilitate these changes via self-insight, greater connectedness with others, and increases in self-compassion, though further research is needed.
- Top Cited Papers
- 27 February 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (1) , 41-47
Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users
Introduction: Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy. There is a surge of interest in psychedelics, and psychedelic-assisted psychotherapy is becoming increasingly accessible. However, most individuals using psychedelics do so outside of therapeutic contexts. It is important to understand the adverse experiences that may occur with psychedelic use, as well as adverse events that may happen even in therapeutic contexts. Materials and Methods: We conducted an anonymous online survey of individuals who self-reported past psychedelic use. We asked about the frequency of experiencing 12 different adverse experiences when using psychedelics, and if they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner. Participants could also describe other adverse experiences. Results: Among 1,221 participants, most reported having adverse experiences such as being frightened (74.3%), sadness (58.6%), feeling their body shake or tremble (54.3%), and loneliness (51.6%) during their psychedelic experiences. About half of participants reported having some other adverse experience, and one in ten participants had adverse physical reactions. About one-third of participants knew someone who was arrested for possession or use of psychedelics; 8% reported that they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner; and one-quarter of participants knew someone who experienced a severe adverse event other than inappropriate sexual contact or arrest. Conclusion: Despite beneficial effects, psychedelic experiences can also be challenging, distressing, or even harmful. Adverse events can increase the risks of psychological harm, legal problems, stigma, and public health issues. Therefore, it is essential to prevent, identify, manage, and treat adverse events during psychedelic experiences to ensure the safety and well-being of the participants and the facilitators, and create opportunities for “integration” even with unguided sessions.
- 27 February 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (1) , 41-47
Top Cited PapersPsychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users
Introduction: Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy. There is a surge of interest in psychedelics, and psychedelic-assisted psychotherapy is becoming increasingly accessible. However, most individuals using psychedelics do so outside of therapeutic contexts. It is important to understand the adverse experiences that may occur with psychedelic use, as well as adverse events that may happen even in therapeutic contexts. Materials and Methods: We conducted an anonymous online survey of individuals who self-reported past psychedelic use. We asked about the frequency of experiencing 12 different adverse experiences when using psychedelics, and if they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner. Participants could also describe other adverse experiences. Results: Among 1,221 participants, most reported having adverse experiences such as being frightened (74.3%), sadness (58.6%), feeling their body shake or tremble (54.3%), and loneliness (51.6%) during their psychedelic experiences. About half of participants reported having some other adverse experience, and one in ten participants had adverse physical reactions. About one-third of participants knew someone who was arrested for possession or use of psychedelics; 8% reported that they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner; and one-quarter of participants knew someone who experienced a severe adverse event other than inappropriate sexual contact or arrest. Conclusion: Despite beneficial effects, psychedelic experiences can also be challenging, distressing, or even harmful. Adverse events can increase the risks of psychological harm, legal problems, stigma, and public health issues. Therefore, it is essential to prevent, identify, manage, and treat adverse events during psychedelic experiences to ensure the safety and well-being of the participants and the facilitators, and create opportunities for “integration” even with unguided sessions.
- 5 February 2025
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 58 (3) , 1-7
Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use
Psychedelic drugs are currently being explored for their therapeutic potential for a variety of health conditions. The recent increased public interest in psychedelics necessitates empirical investigation into motivations for use among users as well as how motivations may change over time. We asked a large sample of participants reporting naturalistic psychedelic use (N = 1221) about their motivations for using psychedelics initially (i.e. their first time) as well as currently. We found that motivations for psychedelic use change substantially over time, with initial use typically for recreation or exploration, and later use more for therapeutic or personal growth reasons, including managing mental health conditions, growing spiritually, connecting with nature, improving creativity, and managing trauma. These results highlight the distinct and shifting motivations for engaging in psychedelic use. Although the study was limited by a retrospective design, it is the first to show that motivations for using psychedelics may change over time, with initial use focused on recreation and curiosity but subsequent use more motivated by self-improvement (e.g. enhancing relationships and health). Future prospective designs and qualitative interviews may aid in further elucidating the mechanisms underlying these shifts in motivations over time.
- 5 February 2025
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 58 (3) , 1-7
Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use
Psychedelic drugs are currently being explored for their therapeutic potential for a variety of health conditions. The recent increased public interest in psychedelics necessitates empirical investigation into motivations for use among users as well as how motivations may change over time. We asked a large sample of participants reporting naturalistic psychedelic use (N = 1221) about their motivations for using psychedelics initially (i.e. their first time) as well as currently. We found that motivations for psychedelic use change substantially over time, with initial use typically for recreation or exploration, and later use more for therapeutic or personal growth reasons, including managing mental health conditions, growing spiritually, connecting with nature, improving creativity, and managing trauma. These results highlight the distinct and shifting motivations for engaging in psychedelic use. Although the study was limited by a retrospective design, it is the first to show that motivations for using psychedelics may change over time, with initial use focused on recreation and curiosity but subsequent use more motivated by self-improvement (e.g. enhancing relationships and health). Future prospective designs and qualitative interviews may aid in further elucidating the mechanisms underlying these shifts in motivations over time.
- 19 September 2024
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 57 (5) , 475-485
Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use
Psychedelic-assisted therapy (PAT) has shown preliminary efficacy for psychiatric and physical health conditions. Although some people report naturalistic psychedelic use with so-called "underground" practitioners, little is known about PAT that occurs outside of controlled clinical settings or perspectives of these practitioners. We conducted an anonymous online survey of individuals who reported providing psychedelic support services (e.g. trip sitting and/or preparatory/follow-up psychotherapy) in naturalistic settings. We investigated demographics, including education and licensing, details about services provided, and reported client outcomes. Among 107 participants, 40.2% held a full or in-progress license and 44.9% had not obtained a relevant graduate degree. Almost all participants reported pre-screening clients before treatment, offering preparation, integration, and trip-sitting services, and most employed a range of therapeutic modalities, centering primarily on non-directive approaches. Participants reported that clients most commonly consumed psilocybin, and treated numerous conditions, primarily aligning with indications targeted in psychedelic clinical research. Perceptions of clients' symptom changes were largely positive, although a small proportion reported worsened personality disorder symptoms. Further research delineating client and practitioner perspectives of naturalistic PAT services is warranted, and such work may shed light on the benefits and risks specific to naturalistic PAT as well as inform best practices for practitioners.
- 19 September 2024
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 57 (5) , 475-485
Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use
Psychedelic-assisted therapy (PAT) has shown preliminary efficacy for psychiatric and physical health conditions. Although some people report naturalistic psychedelic use with so-called "underground" practitioners, little is known about PAT that occurs outside of controlled clinical settings or perspectives of these practitioners. We conducted an anonymous online survey of individuals who reported providing psychedelic support services (e.g. trip sitting and/or preparatory/follow-up psychotherapy) in naturalistic settings. We investigated demographics, including education and licensing, details about services provided, and reported client outcomes. Among 107 participants, 40.2% held a full or in-progress license and 44.9% had not obtained a relevant graduate degree. Almost all participants reported pre-screening clients before treatment, offering preparation, integration, and trip-sitting services, and most employed a range of therapeutic modalities, centering primarily on non-directive approaches. Participants reported that clients most commonly consumed psilocybin, and treated numerous conditions, primarily aligning with indications targeted in psychedelic clinical research. Perceptions of clients' symptom changes were largely positive, although a small proportion reported worsened personality disorder symptoms. Further research delineating client and practitioner perspectives of naturalistic PAT services is warranted, and such work may shed light on the benefits and risks specific to naturalistic PAT as well as inform best practices for practitioners.
- Open Access
- 4 August 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1224551
Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Introduction: There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and healthcare providers (psychiatrist, therapist, or primary physicians), and use characteristics.Methods: We conducted an online, anonymous, confidential, cross-sectional survey of adults reporting psychedelic use (N = 1221) through a psychedelics advocacy event and social media between 9/18/2022 and 11/5/2022. We assessed participant disclosure of psychedelic use with their psychiatric care provider (PsyCP) and/or primary care provider (PCP), desire for provider support, access to support, and rate of taking prescribed psychoactive medications alongside psychedelics.Results: Among participants with such care providers, 22% disclosed psychedelic use to their PCP vs. 58% to their PsyCP. Participants were less confident in PCP vs. PsyCP ability to integrate psychedelics into treatment. Common reasons for nondisclosure included stigma, inadequate provider knowledge, and legal concerns. 23% reported taking psychedelics on the same day as potentially interacting psychiatric medications (e.g., anxiolytics, antidepressants). Despite 81% of participants desiring therapist support during psychedelic experiences, only 15% had received such support.Discussion: Our results show that psychedelic use is generally disconnected from primary and psychiatric clinical care. This disconnection may result in safety issues, including inadequate screening for contraindicated conditions, lack of support during emergent adverse events, and drug interactions. Enhanced clinical education and orienting drug policy towards known harms and benefits of psychedelics is needed.
- 4 August 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1224551
Open AccessSlouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Introduction: There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and healthcare providers (psychiatrist, therapist, or primary physicians), and use characteristics.Methods: We conducted an online, anonymous, confidential, cross-sectional survey of adults reporting psychedelic use (N = 1221) through a psychedelics advocacy event and social media between 9/18/2022 and 11/5/2022. We assessed participant disclosure of psychedelic use with their psychiatric care provider (PsyCP) and/or primary care provider (PCP), desire for provider support, access to support, and rate of taking prescribed psychoactive medications alongside psychedelics.Results: Among participants with such care providers, 22% disclosed psychedelic use to their PCP vs. 58% to their PsyCP. Participants were less confident in PCP vs. PsyCP ability to integrate psychedelics into treatment. Common reasons for nondisclosure included stigma, inadequate provider knowledge, and legal concerns. 23% reported taking psychedelics on the same day as potentially interacting psychiatric medications (e.g., anxiolytics, antidepressants). Despite 81% of participants desiring therapist support during psychedelic experiences, only 15% had received such support.Discussion: Our results show that psychedelic use is generally disconnected from primary and psychiatric clinical care. This disconnection may result in safety issues, including inadequate screening for contraindicated conditions, lack of support during emergent adverse events, and drug interactions. Enhanced clinical education and orienting drug policy towards known harms and benefits of psychedelics is needed.
- 20 April 2023
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 55 (5) , 631-639
“How Do I Learn More About this?”: Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics
There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-seeking behavior of people using psychedelics naturalistically, given the importance of preparation and harm-reduction. We examined sources of information for people using psychedelics naturalistically, and the degree to which they are trusted in a large, anonymous, online survey (N = 1221). The most common source of participants’ information on psychedelics was their own experimentation and experiences (79.52%). Most also sought information from Internet websites (61.67%), friends (61.02%), Internet discussion forums (57.08%), books (57%), and articles in peer-reviewed scientific journals (54.55%). Few sought information from their primary health care provider (4.83%). Articles published in scientific journals, psychedelic nonprofits, and researchers based in colleges or universities were the most trusted sources of psychedelic information. Government agencies and pharmaceutical companies were the least trusted. Few participants thought that the popular media accurately stated the benefits and risks of psychedelics and most thought that the popular media failed to distinguish between different types of psychedelics. Our results indicate a high level of information seeking among psychedelic users, with a diverse array of information sources typically outside of mainstream health and medical care systems.
- 20 April 2023
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 55 (5) , 631-639
“How Do I Learn More About this?”: Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics
There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-seeking behavior of people using psychedelics naturalistically, given the importance of preparation and harm-reduction. We examined sources of information for people using psychedelics naturalistically, and the degree to which they are trusted in a large, anonymous, online survey (N = 1221). The most common source of participants’ information on psychedelics was their own experimentation and experiences (79.52%). Most also sought information from Internet websites (61.67%), friends (61.02%), Internet discussion forums (57.08%), books (57%), and articles in peer-reviewed scientific journals (54.55%). Few sought information from their primary health care provider (4.83%). Articles published in scientific journals, psychedelic nonprofits, and researchers based in colleges or universities were the most trusted sources of psychedelic information. Government agencies and pharmaceutical companies were the least trusted. Few participants thought that the popular media accurately stated the benefits and risks of psychedelics and most thought that the popular media failed to distinguish between different types of psychedelics. Our results indicate a high level of information seeking among psychedelic users, with a diverse array of information sources typically outside of mainstream health and medical care systems.